- Home
- BTSG vs BEAM Comparison
BTSG vs BEAM Comparison
Compare BTSG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTSG
- BEAM
- Stock Information
- Founded
- BTSG 1974
- BEAM 2017
- Country
- BTSG United States
- BEAM United States
- Employees
- BTSG N/A
- BEAM N/A
- Industry
- BTSG
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTSG
- BEAM Health Care
- Exchange
- BTSG NYSE
- BEAM Nasdaq
- Market Cap
- BTSG 4.1B
- BEAM 1.6B
- IPO Year
- BTSG 2024
- BEAM 2020
- Fundamental
- Price
- BTSG $20.31
- BEAM $21.16
- Analyst Decision
- BTSG Strong Buy
- BEAM Strong Buy
- Analyst Count
- BTSG 9
- BEAM 11
- Target Price
- BTSG $23.50
- BEAM $48.90
- AVG Volume (30 Days)
- BTSG 2.9M
- BEAM 2.3M
- Earning Date
- BTSG 08-01-2025
- BEAM 08-05-2025
- Dividend Yield
- BTSG N/A
- BEAM N/A
- EPS Growth
- BTSG N/A
- BEAM N/A
- EPS
- BTSG 0.29
- BEAM N/A
- Revenue
- BTSG $11,858,835,000.00
- BEAM $63,578,000.00
- Revenue This Year
- BTSG $11.55
- BEAM N/A
- Revenue Next Year
- BTSG $12.14
- BEAM $17.18
- P/E Ratio
- BTSG $86.20
- BEAM N/A
- Revenue Growth
- BTSG 30.55
- BEAM N/A
- 52 Week Low
- BTSG $10.15
- BEAM $13.53
- 52 Week High
- BTSG $25.57
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- BTSG 33.01
- BEAM 65.49
- Support Level
- BTSG $21.36
- BEAM $19.02
- Resistance Level
- BTSG $22.40
- BEAM $22.51
- Average True Range (ATR)
- BTSG 0.71
- BEAM 1.15
- MACD
- BTSG -0.27
- BEAM 0.49
- Stochastic Oscillator
- BTSG 1.84
- BEAM 78.91
About BTSG BRIGHTSPRING HEALTH SERVICES INC
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.